Physician profile
Patrick C Buczynski
NPI 1154697514
$3,995.06
in general payments reported to CMS, 2019-2025
36 companies · $423 in 2025
The $423 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $1,251 · 2021: $16.97 · 2022: $316 · 2023: $395 · 2024: $673 · 2025: $423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $580.72 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $531.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $391.99 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $284.91 | 2019-2024 | Otezla, Repatha |
| Allergan, INC. | $275.47 | 2020 | |
| Pfizer INC. | $243.16 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $224.14 | 2023-2025 | |
| Abbvie INC. | $139.95 | 2019-2024 | Vraylar |
| Sanofi-Aventis U.S. LLC | $137.80 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.54 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $128.75 | 2019-2020 | |
| Lilly USA, LLC | $106.99 | 2019-2024 | Mounjaro, Zepbound |
| Teva Pharmaceuticals USA, INC. | $100.00 | 2020 | |
| Amarin Pharma, INC. | $99.65 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.22 | 2019-2024 | Ofev, Jardiance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $51.64 | 2022-2024 | Eliquis, Camzyos |
| Xeris Pharmaceuticals, INC. | $41.39 | 2024-2025 | Gvoke Hypopen |
| Shire North American Group INC | $36.95 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $36.86 | 2022 | |
| Radius Health, INC. | $35.36 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.56 | 2023-2024 | |
| Sanofi Pasteur INC. | $28.09 | 2019 | |
| Inspire Medical Systems, INC. | $27.23 | 2024 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $26.01 | 2019-2022 | |
| Kyowa Kirin, INC. | $25.49 | 2023 | Crysvita |
| Sunovion Pharmaceuticals INC. | $22.78 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.97 | 2024 | Givlaari |
| Daiichi Sankyo INC. | $18.65 | 2023 | Injectafer |
| Lundbeck LLC | $17.27 | 2023 | Vyepti |
| Regeneron Healthcare Solutions, INC. | $16.07 | 2019 | |
| Phathom Pharmaceuticals, INC. | $16.07 | 2024 | Voquezna |
| Alexion Pharmaceuticals, INC. | $15.27 | 2020 | |
| Merck Sharp & Dohme LLC | $13.99 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.22 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.76 | 2020 | |
| Grifols USA, LLC | $12.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Buczynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.